key: cord-0826706-bvpd083y
authors: Arabpour, Erfan; Khoshdel, Sina; Tabatabaie, Negin; Akhgarzad, Ali; Zangiabadian, Moein; Nasiri, Mohammad Javad
title: Stem Cells Therapy for COVID-19: A Systematic Review and Meta-Analysis
date: 2021-11-29
journal: Front Med (Lausanne)
DOI: 10.3389/fmed.2021.737590
sha: 3f3a6c6ccf75775858adb3b88981b6cfeb367262
doc_id: 826706
cord_uid: bvpd083y

Introduction: Vaccination seems to be a good solution for preventing and controlling coronavirus disease (COVID-19) pandemic, but still there are some challenges in COVID-19 vaccination. Investigating new therapeutic options for COVID-19 is necessary. The current study aimed to evaluate the safety and efficacy of stem cells in treating patients with COVID-19. Methods: We reviewed the relevant scientific literature published up to April 1, 2021. The pooled risk ratio (RR) with 95% CI was assessed using a fixed or random-effect model. We considered P < 0.05 as statistically significant for publication bias. Data were analyzed by Comprehensive Meta-Analysis software, Version 2.0 (Biostat, Englewood, NJ). Results: After reviewing 1,262 records, we identified 10 studies that met the inclusion criteria. The analysis showed that stem cell therapy could significantly reduce the mortality rate (RR 0.471, 95% CI: 0.270–0.821) and morbidity (RR 0.788, 95% CI: 0.626–0.992) in patients with COVID-19; compared with the control group. Conclusions: The present study suggests that stem cell therapy has a remarkable effect on reducing mortality and morbidity of patients with COVID-19. Further large-scale studies are needed to approve these results. Defining a protocol for stem cell therapy in patients with COVID-19 can lead to achieving the best clinical outcomes.

Since the primary detection of coronavirus disease in December 2019 in Wuhan, China, it has caused more than 175 million infected cases and 3.7 million deaths up to June 10, 2021, all over the world (1) . COVID-19 pandemic has been putting a massive mental, health, social, and economic burden on individuals and societies (2, 3) .

Vaccination has been shown to be a good solution for this problem. However, vaccines have some limitations, including, they are for prevention and not for treatment. Their protection is not 100%, and their distribution worldwide is unfair (4, 5) .

A broad spectrum of treatments was introduced for COVID-19, such as remdesivir, favipiravir, corticosteroids, tocilizumab, hydroxychloroquine, and convalescent plasma therapy (4, 5) . Furthermore, another therapeutic option is stem cell therapy (6, 7) . Stem cells are used in the treatment of a wide variety of diseases, from autoimmune diseases (8) to heredity (9) and infectious diseases (10) . Mechanisms, which include immunomodulation, regenerative ability, clearance of alveolar fluid, and preventing thrombotic events, drive the researchers to use these cells to treat COVID-19 (11) . Mesenchymal stem cells (MSCs) are shown to be effective in reducing inflammation by releasing chemokines (CCL5, CXCL9, 10, 11) and other factors [transforming growth factor-beta (TGF-β), nitric oxide (NO)/indoleamine 2,3-dioxygenase (IDO), prostaglandin E2 (PGE2)] in their secretomes. The immunomodulation mechanisms include: (a) inhibiting B cells, T cells, and natural killer (NK) cells FIGURE 1 | Flow chart of study selection for inclusion in the systematic review and meta-analysis. proliferation and activity; (b) inhibiting maturation and antigen-presenting of dendritic cells; (c) enhancing M2 macrophage activation; and (d) restraining cytokine storm (12) (13) (14) . This anti-inflammatory property has such importance that MSCs are used to prevent graft vs. host disease (GvHD) in many organ transplantations (15) . Some studies reported that stem cells could reduce mortality rate and improve pulmonary function and disease remission in patients with COVID-19. However, a comprehensive analysis on this issue has not yet been performed. The current study aimed to evaluate the safety and efficacy of stem cells in treating patients with COVID-19. 

The records found through database searching were merged, and the duplicates were removed using EndNote X7 (Thomson Reuters, New York, NY, USA). Two reviewers independently screened the records by title/abstract and full texts to exclude those unrelated to the study topic. The studies included met the following inclusion criteria: (i) patients were diagnosed with COVID-19 based on the WHO criteria; (ii) patients were treated with stem cells; and (iii) treatment outcomes were recorded. Conference abstracts, editorials, reviews, and experimental studies on animal models were excluded.

Two reviewers designed a data extraction form. These reviewers extracted data from all eligible studies, and differences were resolved by consensus. The following data were extracted: first author name; year of publication; type of epidemiological study, country/ies where the research was conducted; treatment protocols, demographics, adverse effects, and outcomes.

The checklists provided by the Joanna Briggs Institute (JBI) for randomized controlled trials (RCTs) were used to perform the quality assessment (17) .

The pooled risk ratios (RRs) with 95% CI were assessed using random or fixed-effect models. The random-effects model was used because of the estimated heterogeneity of the true effect sizes. The between-study heterogeneity was assessed by Cochran's Q and the I 2 statistic. Publication bias was evaluated statistically by using Egger's and Begg's tests as well as the funnel plot (p < 0.05 was considered indicative of statistically significant publication bias; funnel plot asymmetry also suggests bias). All analyses were performed using "Comprehensive Meta-Analysis" software, Version 2.0 (Biostat, Englewood, NJ).

Studies included and excluded through the review process are summarized in Figure 1 . A total of 1,262 records were found in the initial search; after removing duplicate articles, and full-text review, 10 were chosen (Figure 1) . Of the included studies, there were five non-randomized clinical trials and five RCTs ( Table 1) . Totally, 184 patients underwent stem cell therapy, while 161 patients took part as controls. Most studies assessed mortality, morbidity, adverse event (AE) and severe adverse event (SAE), pulmonary function, imaging changes, systematic symptoms, and inflammatory markers.

Based on the JBI checklist for experimental studies, the included studies had a low risk of bias ( Table 2) .

The origins of studies were six countries: China (n = 5) (18, 20, 22, 24, 25) , United States (n = 1) (23), Germany (n = 1) (19) , Turkey (n = 1) (21), UAE (n = 1) (26), and Russia (n = 1) (27) . In these 10 studies, the age range for stem cell groups was 39-64 and 48-64 for control groups. Except for two studies (22, 27) , which did not report comorbidities of the study population, diabetes mellitus (34 of 138 cases) and hypertension (40 of 138 cases) were the most common reported comorbidities ( Table 3) .

Among the 10 studies, four used umbilical cord-derived MSC (UC-MSC) (18, (23) (24) (25) , one pericytes-derived MSC (21), one menstrual blood-derived MSC (22) , one non-hematopoietic peripheral blood stem cells (NHPBSC) (26) , and one used MSCs-derived exosomes (27) . Two studies did not report the type of MSC (19, 20) . In dosing, four studies administered 1-2 × 10 6 cells per kg of body weight (19) (20) (21) 25) , four administered 30-120 million cells per infusion (18, (22) (23) (24) , one used 0/5-2 × 10 10 of MSC-derived exosomes per administration (27) , and one did not report stem cell dose (26) . Of the 184 patients in the stem cell group, 27 received a single dose, 35 received two doses, 102 received three doses of therapy, and 20 received therapy for 20 doses. Route of delivery was intravenous (IV) in nine studies and inhalation in one study (27) ( Table 4 ).

Severe Adverse Events

None of the 10 studies reported treatment-related SAEs. Furthermore, none of the 13 deaths in stem cell groups were related to cell infusion ( Table 5) .

Two studies reported minimal infusion-related AE in the stem cell group. In both the studies, the incidence of AE in the MSC group was less than in the control group. All other seven studies reported no cell infusion-related AE ( Table 5) . 

In three studies, all participated patients survived (18, 24, 27) .

In seven remained studies, the total mortality rate for the stem cell group was %14/4 (13 of 90) and %32/7 (35 of 107) for the control group. Our meta-analysis showed that stem cell therapy could significantly decrease the mortality rate in patients with COVID-19 (RR 0.471, 95% CI 0.270-0.821) (Figure 2) .

The results of Egger's and Begg's tests did not show any evidence of publication bias (The P-value of Egger's tests was 0.1, and Begg's tests was 0.5) (Figure 3 ).

Stem cell therapy could significantly decrease morbidities in patients with COVID-19 (RR 0.788, 95% CI 0.626-0.992) (Figure 4) . Egger's and Begg's tests indicated significant publication bias (The P-value of Egger's tests was 0.001, and Begg's tests was 0.047) (Figure 5 ).

Pulmonary function and imaging changes have been assessed in seven studies (18-22, 24, 25) . These studies showed that stem cell therapy could improve O 2 saturation, Murray score, and lung lesions ( Table 6) .

Systematic changes were defined as any changes from the overall baseline status. Except for one study that had not reported these changes (27) , these data are available for the other nine studies in Table 6 .

Except for one study that had not reported the changes in inflammatory cells and cytokines (27) , these changes are available for the other nine studies in Table 6 .

In the current study, we found that stem cells are safe and can significantly decrease the mortality and morbidity of patients with COVID-19. Stem cell infusion can also improve pulmonary function, ameliorate symptoms, and suppress inflammation.

Safety is the primary issue that should be considered for any therapy. In our included studies, none of the mortalities were related to cell infusion. Thompson et al. (28) showed that intravascular administration of MSCs is associated with an increased fever risk (RR = 2.48, 95% CI 1.27-4.86). One of the most common symptoms in patients with COVID-19 is fever. In our studies, just Meng et al. (18) reported that two patients with MSC developed fever immediately after infusion, which resolved without intervention within 4 h, and none of the other studies reported infusion-related fever. So it seems stem cell transplantation is safe in patients with COVID-19.

Our analysis showed that stem cell therapy could significantly reduce disease mortality and severity. Qu et al. (29) conducted a meta-analysis of human studies on acute respiratory distress syndrome (ARDS). ARDS is a significant cause of mortality in patients with COVID-19. They reported that MSC therapy could reduce mortality in patients with ARDS but was not statistically significant. This dissimilarity could be due to study design and baseline characteristics; we just included patients with COVID-19, but Qu et al. included patients with ARDS with various ARDS causes like COVID-19, influenza, sepsis, and aspiration.

Based on the evaluation of the pulmonary function, and inflammatory markers changes in the included studies, MSC therapy could reduce inflammation and enhance pulmonary function. Similarly, a systematic review by Mahendiratta et al. (30) suggests that MSCs are capable of reducing systemic inflammation and protecting patients against COVID-19 infection. It seems the mechanism of action is due to the immunomodulatory effect of MSCs; which involves: (a) inhibiting B cells, T cells, NK cells, and dendritic cells activation; (b) decreasing macrophage M1 and enhancing macrophage M2 activation; (c) inhibition of mast cell degranulation; (d) promoting T regulatory and Th2 cell (31) .

Interleukin 6 (IL-6) is a prognostic marker in COVID-19 infection, and tocilizumab blocks its receptors, a drug of choice for COVID-19 infection (32) . Our data show that MSCs can reduce IL-6 in serum, which means that MSCs can mimic tocilizumab by decreasing IL-6 activity. Das (33) proposes that the anti-inflammatory effect of MSCs is attributable to the ability to secreting lipoxin A4 (LXA4), PGE2, and their precursors, which prevent the production of pro-inflammatory cytokines like IL-6 and tumor necrosis factor-alpha (TNF-α); this feature could be engaged to confront "cytokine storm" that which is seen in COVID-19 infection.

One complication of COVID-19 is excessive lung fluid production and pulmonary edema, which disturb proper pulmonary function. MSCs release keratinocyte growth factor (KGF), angiopoietin-1, and LXA4 in their exosomes. These factors activate the Na+-K+ pump, thus reducing the permeability of the alveolar epithelium to proteins and fluid and inhibiting fluid accumulation in lung tissue and edema. Another complication of COVID-19 is lung fibrosis. This complication should be taken seriously because it is irreversible if it occurs. MSCs prevent lung fibrosis by two mechanisms: (a) differentiating to alveolar type II cells; (b) paracrine signals (like KGF) that induce proliferation and inhibit apoptosis in type II alveolar cells (11, 34) .

An important question is: Whether MSCs can get infected by COVID-19? Researches have shown that COVID-19 uses angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) as receptors to enter cells and infect them. Avanzini et al. (35) and Schäfer et al. (36) in their in vitro studies found that both fetal and adult MSCs have a deficient expression of ACE2 and TMPRSS2. Hernandez et al. (37) reported the same result in human UC-MSCs. However, Desterke et al. (38) reported that adult MSCs express ACE2 highly, while placenta-derived MSCs express ACE2 at a low level and only in initial passages of cultures. Anyhow, it seems MSCs are resistant to get infected by COVID-19 by low expression of ACE2 and TMPRSS2, which will cause them to dodge the infection and perform their immunomodulatory functions.

The COVID-19 mortality rate is higher among immunocompromised patients (39) , and as we discussed before, MSCs modulate the immune response. So MSCs infusion for an immunocompromised patient may exacerbate the infection. There is still no large-scale clinical trial that evaluates the safety and efficacy of cell infusion for COVID-19 infection in immunocompromised patients. However, many patients in our studies received corticosteroids during the trial, which suppressed the immune system, and cell infusion was still safe and effective. Cui et al. (40) , in an in vitro study, found that coculturing of human MSCs and NK cells of immunocompromised patients can improve the function of impaired NK cells and enhance the synthesis of interferon-gamma (IFN-γ) (which is a crucial part of the innate immune response during viral infection). Also, Lim et al. (41) found that human MSCs reduce lung injury in severe combined immunodeficiency (SCID) mice but not in immunocompetent mice.

Unfortunately, there is no protocol for stem cell therapy in patients with COVID-19. So trials are heterogeneous in terms of stem cell source, culture, dose, delivery route, and even the stage of COVID-19 infection that MSCs are administered. Despite these heterogeneities in reviewed studies, they all reported stem Meng et al. (18) 0/9 0/9 1/9 4/9 CT images showed lung lesions entirely faded away within 2 weeks after MSC infusion, while lung lesions still existed in one severe patient in the control group at discharge Clinical symptoms at discharge; respectively, for MSC and control group: (Fever: 5/9; 2/9), (Fatigue: 4/9; 5/9), (Cough: 4/9; 8/9) and (breath shortness: 1/9; 5/9). The period of admission to discharge was same in MSC and control group (20.00 vs. 23.00 days, P = 0.306)

There was a reduced trend in IFN-γ, TNF-α, MCP-1, IP-10, ICU stay in control was less than the MSC group but not significant (P = 0.07) (due to the higher incidence of deceased patients within the control group and a higher percentage of ECMO use in the MSC group). The incidence of kidney injury and hepatic failure in the MSC group did not differ from the incidence in the control group of patients cell therapy as a safe and effective treatment for patients with COVID-19. Large-scale RCTs with accurate methodology will help to develop the best protocol in this field. Some limitations of this study should be taken into consideration. First, although we started with a large number of articles, after several screenings, the number of eligible studies was relatively small. This could have reduced the power of the conclusion. Second, the potential influence of preexisting conditions, the severity of infection, and the COVID-19 variants could not be investigated because of the limited information obtained from the studied articles. Third, as with any systematic review, limitations associated with potential publication bias should be considered. Furthermore, studies' variability, different patients' characteristics, different morbidity definitions, and wide range of outcome metrics for pulmonary changes and inflammatory indicators were other limitations.

Our analysis demonstrated that stem cells are safe to use in patients with COVID-19 and could significantly reduce mortality and morbidity rate in infected patients. Due to the low number of included studies, a large-scale analysis is needed to measure the outcomes. Likewise, a protocol for stem cell therapy in COVID-19 infection should be defined to achieve the best possible clinical outcomes.

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

Economic, social and political issues raised by the COVID-19 pandemic

COVID-19 pandemic and mental health consequences: systematic review of the current evidence

Treatment options for COVID-19: a review

COVID-19 diagnosis and management: a comprehensive review

When stem cells meet graphene: opportunities and challenges in regenerative medicine

Stem cell-based regenerative medicine

Mesenchymal stem cell therapy for autoimmune disease: risks and rewards

Induced pluripotent stem cell technology for modelling and therapy of cerebellar ataxia

Mesenchymal stem cells and infectious diseases: smarter than drugs

Proposed mechanisms of targeting COVID-19 by delivering mesenchymal stem cells and their exosomes to damaged organs

Mesenchymal stem cell and regenerative medicine: regeneration versus immunomodulatory challenges

Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential

Mesenchymal stem cell-based immunomodulation: properties and clinical application

Mesenchymal stem cell as salvage treatment for refractory chronic GVHD

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR-and XDR-TB: a multicentre study

Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial

Mesenchymal stem cell therapy for severe COVID-19 ARDS

Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia

MSC transplantation in eight severe COVID-19 patients: can cytokine storm be reversed?

Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: an exploratory clinical trial

Umbilical cord mesenchymal stem cells for COVID-19 ARDS: a double blind, phase 1/2a, randomized controlled trial

Treatment with human umbilical cord-derived mesenchymal stem cells for COVID-19 patients with lung damage: a randomised, double-blind, placebo controlled phase 2 trial. medRxiv

Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells

Renal involvement in patients with covid-19 pneumonia and outcomes after stem cell nebulization

Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia

Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and metaanalysis

Cell-based therapy to reduce mortality from COVID-19: systematic review and metaanalysis of human studies on acute respiratory distress syndrome

Stem cell therapy in COVID-19: pooled evidence from SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: a systematic review

Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatmen

Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial

Bioactive lipids as mediators of the beneficial action (s) of mesenchymal stem cells in COVID-19

Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics

Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection

Human mesenchymal stromal cells are resistant to SARS-CoV-2 infection under steady-state, inflammatory conditions and in the presence of SARS-CoV-2-infected cells

Dodging COVID-19 infection: low expression and localization of ACE2 and TMPRSS2 in multiple donor-derived lines of human umbilical cord-derived mesenchymal stem cells

Molecular investigation of adequate sources of mesenchymal stem cells for cell therapy of COVID-19-associated organ failure

COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients

Human mesenchymal stromal/stem cells acquire immunostimulatory capacity upon cross-talk with natural killer cells and might improve the NK cell function of immunocompromised patients

Human mesenchymal stem cells reduce lung injury in immunocompromised mice but not in immunocompetent mice

This study was supported by Shahid Beheshti University of Medical Sciences, Tehran, Iran.

The study was designed by MZ and MN. EA, SK, NT, and AA performed the search, study selection, and data extraction. Statistical analysis was performed by MN. The first draft of the manuscript was written by MZ, EA, SK, NT, and AA. MN and MZ revised the article. All authors contributed to the article and approved the submitted version.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.The reviewer AB declared a shared affiliation with the authors to the handling editor at the time of review.